Indication intelligence, analysis and sector perception

BioLife Solutions (BLFS) closes 5.95 million share offering priced at $14.50

July 8, 2020 12:11pm

BLFS' underwriters' option included an additional 776,250 shares

The gross proceeds from the offering to BLFS, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $86 million.

There was never any worry it would not get done ...

Cowen, Oppenheimer & Co. and Stephens Inc. acted as joint book-running managers for the proposed offering. B. Riley FBR, Maxim Group LLC and Northland Capital Markets acted as co-managers for the offering.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 48 min ago
RegMed Investors (RMi) Closing Bell: sector ascended after being under pressure

3 hours 3 min ago
RegMed Investors (RMi): Happy soon to be New Year – 2025

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.